Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468
Alexander Treiber, Ruben de Kanter, Catherine Roch, et al.
Journal of Pharmacology and Experimental Therapeutics (2017) Vol. 362, Iss. 3, pp. 489-503
Open Access | Times Cited: 69

Showing 1-25 of 69 citing articles:

Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials
Emmanuel Mignot, David Mayleben, Ingo Fietze, et al.
The Lancet Neurology (2022) Vol. 21, Iss. 2, pp. 125-139
Closed Access | Times Cited: 145
Hypocretins (orexins): The ultimate translational neuropeptides
Laura H. Jacobson, Daniël Hoyer, Luı́s de Lecea
Journal of Internal Medicine (2022) Vol. 291, Iss. 5, pp. 533-556
Closed Access | Times Cited: 71
Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder
Yves Dauvilliers, Gary Zammit, Ingo Fietze, et al.
Annals of Neurology (2020) Vol. 87, Iss. 3, pp. 347-356
Closed Access | Times Cited: 110
Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder
Gary Zammit, Yves Dauvilliers, Scott Pain, et al.
Neurology (2020) Vol. 94, Iss. 21
Closed Access | Times Cited: 86
Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders
Clemens Muehlan, Cédric Vaillant, Isabelle Zenklusen, et al.
Expert Opinion on Drug Metabolism & Toxicology (2020) Vol. 16, Iss. 11, pp. 1063-1078
Closed Access | Times Cited: 70
Daridorexant: First Approval
Anthony Markham
Drugs (2022) Vol. 82, Iss. 5, pp. 601-607
Open Access | Times Cited: 56
Comparison of Orexin 1 and Orexin 2 Ligand Binding Modes Using X-ray Crystallography and Computational Analysis
Mathieu Rappas, A. Ali, K.A. Bennett, et al.
Journal of Medicinal Chemistry (2019) Vol. 63, Iss. 4, pp. 1528-1543
Open Access | Times Cited: 65
Accelerated Development of the Dual Orexin Receptor Antagonist ACT‐541468: Integration of a Microtracer in a First‐in‐Human Study
Clemens Muehlan, Jules A. A. C. Heuberger, Pierre‐Éric Juif, et al.
Clinical Pharmacology & Therapeutics (2018) Vol. 104, Iss. 5, pp. 1022-1029
Open Access | Times Cited: 59
Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia
Catherine Roch, Giorgio Bergamini, Michel A. Steiner, et al.
Psychopharmacology (2021) Vol. 238, Iss. 10, pp. 2693-2708
Open Access | Times Cited: 50
Hypocretin/Orexin Receptor Pharmacology and Sleep Phases
Yu Sun, Ryan K. Tisdale, Thomas S. Kilduff
Monographs in clinical neuroscience/Frontiers of neurology and neuroscience/Monographs in neural sciences (2021), pp. 22-37
Open Access | Times Cited: 42
Efficacy and Safety of Daridorexant in Older and Younger Adults with Insomnia Disorder: A Secondary Analysis of a Randomised Placebo-Controlled Trial
Ingo Fietze, Claudio L. Bassetti, David Mayleben, et al.
Drugs & Aging (2022) Vol. 39, Iss. 10, pp. 795-810
Open Access | Times Cited: 32
Emerging and upcoming therapies in insomnia
W.-H. Kim, Ho-Sook Kim
Translational and Clinical Pharmacology (2024) Vol. 32, Iss. 1, pp. 1-1
Open Access | Times Cited: 6
The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia
Sander Brooks, Gabriël E. Jacobs, Peter de Boer, et al.
Journal of Psychopharmacology (2019) Vol. 33, Iss. 2, pp. 202-209
Closed Access | Times Cited: 52
Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration
Clemens Muehlan, Sander Brooks, Rob Zuiker, et al.
European Neuropsychopharmacology (2019) Vol. 29, Iss. 7, pp. 847-857
Closed Access | Times Cited: 49
Structure-based development of a subtype-selective orexin 1 receptor antagonist
Jan Hellmann, Matthäus Drabek, Jie Yin, et al.
Proceedings of the National Academy of Sciences (2020) Vol. 117, Iss. 30, pp. 18059-18067
Open Access | Times Cited: 46
Orexin Signaling: A Complex, Multifaceted Process
Natasha C. Dale, Daniël Hoyer, Laura H. Jacobson, et al.
Frontiers in Cellular Neuroscience (2022) Vol. 16
Open Access | Times Cited: 26
Targeting orexin receptors: Recent advances in the development of subtype selective or dual ligands for the treatment of neuropsychiatric disorders
Alessandro Bonifazi, Fabio Del Bello, Gianfabio Giorgioni, et al.
Medicinal Research Reviews (2023) Vol. 43, Iss. 5, pp. 1607-1667
Closed Access | Times Cited: 13
Orexinergic Receptor Antagonists as a New Therapeutic Target to Overcome Limitations of Current Pharmacological Treatment of Insomnia Disorder
Cecilio Álamo, Jerónimo Sáiz Ruiz, Cristina Zaragozá Arnáez
Actas Españolas de Psiquiatría (2024) Vol. 52, Iss. 2, pp. 172-182
Open Access | Times Cited: 5
Effects of daridorexant on rest/wake activity patterns and drinking in adult rats exposed to chronic ethanol vapor in adolescence
Leslie R. Amodeo, Derek N. Wills, Jason Benedict, et al.
Alcohol (2025)
Open Access
Discovery of IDOR-1117-1680, a dual orexin receptor antagonist with fast onset and short duration of action for the treatment of insomnia
Jean‐Philippe Surivet, Elise M. Jacob, Melanie Keßler, et al.
Bioorganic & Medicinal Chemistry (2025) Vol. 122, pp. 118132-118132
Closed Access
Orexin receptors: possible therapeutic targets for psychiatric disorders
Shigeyuki Chaki
Psychopharmacology (2025)
Closed Access
The Quest for the Best Dual Orexin Receptor Antagonist (Daridorexant) for the Treatment of Insomnia Disorders
Christoph Boss, John Gatfield, Christine Brotschi, et al.
ChemMedChem (2020) Vol. 15, Iss. 23, pp. 2286-2305
Closed Access | Times Cited: 37
Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem
Mike Ufer, Debra Kelsh, Kerri A. Schoedel, et al.
SLEEP (2021) Vol. 45, Iss. 3
Open Access | Times Cited: 31
Orexin Receptor Antagonists and Insomnia
Xin Wu, Tao Xue, Zhouqing Chen, et al.
Current Psychiatry Reports (2022) Vol. 24, Iss. 10, pp. 509-521
Closed Access | Times Cited: 20
Daridorexant for the treatment of insomnia disorder: A systematic review and meta-analysis of randomized controlled trials
Feiyu Jiang, Hang Li, Yanting Chen, et al.
Medicine (2023) Vol. 102, Iss. 7, pp. e32754-e32754
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top